Fosamax and Osteonecrosis of the Jaw: Understanding the Risk and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Specific Risks

In the domain of mass production, the legacy of general health and science information has long emphasized broad wellness principles and the importance of informed patient care. This heritage, rooted in community-focused medical practice, provides a foundation for understanding how therapeutic interventions interact with individual health profiles. As we pivot from this general context to a more specific occupational exposure concern, the focus narrows to the relationship between pharmaceutical agents and adverse outcomes in industrial settings. The transition involves recognizing that the same principles of vigilance and evidence-based inquiry applied to routine health maintenance are equally critical when examining risks associated with chemical exposures in manufacturing environments. Here, the concern shifts from population-level health guidance to the precise evaluation of how a particular compound—such as those used in treatments for bone density—may correlate with rare but serious conditions when encountered in occupational contexts. This pivot requires maintaining the same rigorous, neutral stance toward data interpretation that characterizes responsible health communication, while now directing attention toward the potential implications for workers who may handle or be exposed to such substances during production processes. The bridge thus connects established health literacy frameworks with emerging questions about workplace safety and material stewardship.

Fosamax and Its Mechanism of Action

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation involves bone exposure in the oral cavity, often accompanied by pain, swelling, and infection. Diagnosis is typically based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or radiation-induced osteonecrosis. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to ONJ

Mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current research suggests that bisphosphonates suppress bone turnover, which may impair the jawbone's ability to repair microdamage and respond to local stressors. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research indicates that the unique structure and remodeling dynamics of the jawbone may make it particularly vulnerable to the antiresorptive effects of bisphosphonates, potentially leading to necrosis when combined with local trauma or infection.

Risk Factors for ONJ in Fosamax Users

The risk of ONJ is influenced by several factors. Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Timeline and Incidence of ONJ

Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its incidence in clinical trials was low and not statistically different from placebo, highlighting its rarity. Population-based data provide further context. Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This study, conducted among cancer-free female patients aged 40-89 in the United Kingdom Clinical Practice Research Datalink, underscores that while the relative risk increases with longer exposure, the absolute risk remains small.

Causation Considerations and Warnings

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and the development of ONJ, as well as ruling out other potential causes such as cancer, radiation therapy, or other medications. The presence of known risk factors, such as invasive dental procedures or poor oral hygiene, may contribute to the development of ONJ in patients taking Fosamax. The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information, which includes a specific warning about ONJ and lists risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the low absolute risk and the fact that ONJ can occur spontaneously complicate the assessment of individual causation. In summary, Fosamax is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of additional risk factors. The mechanistic basis involves suppression of bone turnover in the jaw, and the timeline for onset can range from days to months. While the absolute risk is low, patients and clinicians should be aware of the warning signs and consider preventive dental care before and during treatment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the risk of developing osteonecrosis of the jaw from taking Fosamax?

The absolute risk of ONJ in Fosamax users is low, approximately 0.05% after 5 years of treatment. However, the relative risk increases with longer duration of use, being threefold higher after 2-3 years and eightfold after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

How does Fosamax cause osteonecrosis of the jaw?

Fosamax suppresses bone turnover, which may impair the jawbone's ability to repair microdamage and respond to local stressors. The unique structure and remodeling dynamics of the jawbone may make it particularly vulnerable to the antiresorptive effects of bisphosphonates (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the symptoms of osteonecrosis of the jaw?

Symptoms include exposed, non-healing bone in the jaw, often accompanied by pain, swelling, and infection. Diagnosis is based on clinical examination and imaging, ruling out other causes such as malignancy or radiation-induced osteonecrosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.